5GH'un PS Oranı emsallerine kıyasla nasıldır?

5GH Price-To-Sales Oranı ( 12.2 x) açısından benzer ortalamaya ( 1.1 x) kıyasla pahalıdır.

5GH'nin PS Oranı, DE Healthcare Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

5GH Price-To-Sales Oranı ( 12.2 x) baz alındığında, German Healthcare sektör ortalamasına ( 0.5 x) kıyasla pahalıdır.

5GH'nin PS Oranı, Adil PS Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PS Oranıdır.

5GH tahmini Adil Price-To-Sales Price-To-Sales Oranı ( 12.2 7.7 x) ile karşılaştırıldığında pahalıdır.

Gelecekteki nakit akışlarına bakıldığında 5GH 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

5GH 'un değerleme analizi için adil değerinin hesaplanmasında yeterli veri bulunmamaktadır.

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Fiyat tahminini göstermek için yeterli veri yok.

Guardant Health (XTRA:5GH) - Hisse Senedi Fiyatı, Haberler ve Analizler

5GH Stoklara Genel Bakış

A precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. Daha fazla detay

5GH temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Gelirin yılda 23.23% oranında artması öngörülüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Guardant Health, Inc. Rakipler

Fresenius Medical Care

XTRA:FME

€12.3b

SYNLAB

HMSE:SYAB

€2.5b

Fresenius SE KGaA

XTRA:FRE

€18.6b

VITA 34

XTRA:V3V

€72.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Guardant Health
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$50.22
52 Haftanın En Yüksek Seviyesi	US$94.50
52 Haftanın En Düşük Seviyesi	US$27.29
Beta	0.63
11 Aylık Değişim	0%
3 Aylık Değişim	0%
1 Yıllık Değişim	-45.86%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-61.82%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	5GH	DE Healthcare	DE Pazar
7D	0%	0.2%	0.8%
1Y	-45.9%	13.9%	8.6%

Getiri vs. Endüstri: 5GH geçen yıl % 13.9 oranında getiri sağlayan German Healthcare sektörünün gerisinde kaldı.

Getiri vs Piyasa: 5GH geçen yıl % 8.6 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 5GH's price volatile compared to industry and market?
5GH volatility
5GH Average Weekly Movement	n/a
Healthcare Industry Average Movement	4.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 5GH son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 5GH 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2011	1,373	Helmy Eltoukhy	guardanthealth.com

Guardant Health, Inc. Temel Bilgiler Özeti

Guardant Health'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
5GH temel i̇stati̇sti̇kler
Piyasa değeri	€5.05b
Kazançlar(TTM)	-€582.92m
Gelir(TTM)	€414.64m

12.2x

P/S Oranı

-8.7x

F/K Oranı

5GH aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
5GH gelir tablosu (TTM)
Gelir	US$430.76m
Gelir Maliyeti	US$142.63m
Brüt Kâr	US$288.13m
Diğer Giderler	US$893.69m
Kazançlar	-US$605.56m

Son Raporlanan Kazançlar

Sep 30, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-5.91
Brüt Marj	66.89%
Net Kâr Marjı	-140.58%
Borç/Özkaynak Oranı	681.7%

5GH uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

5GH Stoklara Genel Bakış

Ödüller

Risk Analizi

Guardant Health, Inc. Rakipler

XTRA:FME

€12.3b

HMSE:SYAB

€2.5b

XTRA:FRE

€18.6b

XTRA:V3V

€72.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Guardant Health, Inc. Revises Revenue Guidance for the Year 2024

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

Recent updates

Guardant Health, Inc. Revises Revenue Guidance for the Year 2024

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer

Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test

Guardant Health, Inc. to Appeal Federal District Court Verdict

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan

Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan

Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index

Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Health, Inc. Announces Management Changes

Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer

Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer

Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery

Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Guardant Health and the Royal Marsden NHS Foundation Trust Partner on Highly Anticipated TRACC Part C Trial to Use Guardant Reveal(Tm) Blood Test to Help Guide Treatment Decisions in Colorectal Cancer

Guardant Health, Inc. to Showcase New Data at ASCO GI 2023 Demonstrating Utility of its Blood Tests for Patients with Gastrointestinal Cancers

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. and Susan G. Komen(R) Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit from Additional Monitoring or Therapy

Guardant Health Announces Positive Results from Pivotal ECLIPSE Study Evaluating A Blood Test for the Detection of Colorectal Cancer

Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022

Guardant Health, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Guardant Health Introduces GuardantINFINITY Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

Guardant Health, Inc. to Showcase New Data At ESMO 2022 Demonstrating Utility of Its Portfolio of Blood Tests for Advanced-Stage Cancer Patients

Senior Vice President of People recently sold €212k worth of stock

Guardant Health, Inc. Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Daiichi Sankyo and Astrazeneca’S Enhertu® for Treatment of Nsclc Patients with Activating Her2 Mutations

Second quarter 2022 earnings released: US$2.25 loss per share (vs US$0.96 loss in 2Q 2021)

Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022

Guardant Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Guardant Health, Inc. Appoints Steve E. Krognes as Class III Director, Effective June 30, 2022

Guardant Health, Inc. Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-Of-Its Kind Prospective Study At Digestive Disease Week 2022

First quarter 2022 earnings released: US$1.21 loss per share (vs US$1.09 loss in 1Q 2021)

Guardant Health, Inc. Provides Revenue Guidance for the Year 2022

Guardant Health, Inc. Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults